Morphologic instability and cancer invasion.

Multiscale modelling and nonlinear simulation of vascular tumour growth. J Math Biol (2008) 2.18

Nonlinear modelling of cancer: bridging the gap between cells and tumours. Nonlinearity (2010) 2.08

A mathematical model of glioblastoma tumor spheroid invasion in a three-dimensional in vitro experiment. Biophys J (2006) 1.91

Computer simulation of glioma growth and morphology. Neuroimage (2007) 1.83

Multiscale cancer modeling. Annu Rev Biomed Eng (2011) 1.65

Three-dimensional multispecies nonlinear tumor growth--I Model and numerical method. J Theor Biol (2008) 1.57

An evolutionary hybrid cellular automaton model of solid tumour growth. J Theor Biol (2007) 1.55

Prediction of drug response in breast cancer using integrative experimental/computational modeling. Cancer Res (2009) 1.53

Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation. J Math Biol (2008) 1.48

Predictive oncology: a review of multidisciplinary, multiscale in silico modeling linking phenotype, morphology and growth. Neuroimage (2007) 1.39

Three-dimensional multispecies nonlinear tumor growth-II: Tumor invasion and angiogenesis. J Theor Biol (2010) 1.37

Integrated intravital microscopy and mathematical modeling to optimize nanotherapeutics delivery to tumors. AIP Adv (2012) 1.35

Multiparameter computational modeling of tumor invasion. Cancer Res (2009) 1.28

Clonal diversity in carcinomas: its implications for tumour progression and the contribution made to it by epithelial-mesenchymal transitions. Clin Exp Metastasis (2007) 1.23

Tumor heterogeneity: mechanisms and bases for a reliable application of molecular marker design. Int J Mol Sci (2012) 1.15

Nonlinear simulations of solid tumor growth using a mixture model: invasion and branching. J Math Biol (2008) 1.13

Evolution of cell motility in an individual-based model of tumour growth. J Theor Biol (2009) 1.13

Carbonic anhydrase IX interacts with bicarbonate transporters in lamellipodia and increases cell migration via its catalytic domain. J Biol Chem (2011) 1.07

Toward an Ising model of cancer and beyond. Phys Biol (2011) 1.05

Heterogeneous nuclear ribonucleoprotein K and nucleolin as transcriptional activators of the vascular endothelial growth factor promoter through interaction with secondary DNA structures. Biochemistry (2011) 1.03

Fractal analysis in a systems biology approach to cancer. Semin Cancer Biol (2011) 1.02

Front instabilities and invasiveness of simulated avascular tumors. Bull Math Biol (2009) 1.02

Perspectives on tissue interactions in development and disease. Curr Mol Med (2010) 1.00

Physical oncology: a bench-to-bedside quantitative and predictive approach. Cancer Res (2011) 0.98

Cancer stem cell, niche and EGFR decide tumor development and treatment response: A bio-computational simulation study. J Theor Biol (2010) 0.98

An off-lattice hybrid discrete-continuum model of tumor growth and invasion. Biophys J (2010) 0.94

In silico modelling of tumour margin diffusion and infiltration: review of current status. Comput Math Methods Med (2012) 0.90

Mathematical Oncology: How Are the Mathematical and Physical Sciences Contributing to the War on Breast Cancer? Curr Breast Cancer Rep (2010) 0.88

The role of engineering approaches in analysing cancer invasion and metastasis. Nat Rev Cancer (2013) 0.86

Multi-scale, multi-resolution brain cancer modeling. Math Comput Simul (2009) 0.84

Model for in vivo progression of tumors based on co-evolving cell population and vasculature. Sci Rep (2011) 0.84

Multi-scale agent-based modeling on melanoma and its related angiogenesis analysis. Theor Biol Med Model (2013) 0.84

Predictions of tumour morphological stability and evaluation against experimental observations. J R Soc Interface (2010) 0.84

Morphological instability and cancer invasion: a 'splashing water drop' analogy. Theor Biol Med Model (2007) 0.83

A novel chemotaxis assay in 3-D collagen gels by time-lapse microscopy. PLoS One (2012) 0.83

An Adaptive Multigrid Algorithm for Simulating Solid Tumor Growth Using Mixture Models. Math Comput Model (2011) 0.82

Modeling tumor cell shedding. Eur Biophys J (2009) 0.82

Computational systems biology in cancer: modeling methods and applications. Gene Regul Syst Bio (2007) 0.81

Shape in migration: quantitative image analysis of migrating chemoresistant HCT-8 colon cancer cells. Cell Adh Migr (2013) 0.80

Diffusion-limited tumour growth: simulations and analysis. Math Biosci Eng (2010) 0.79

A stable scheme for a nonlinear, multiphase tumor growth model with an elastic membrane. Int J Numer Method Biomed Eng (2014) 0.79

Front instabilities and invasiveness of simulated 3D avascular tumors. PLoS One (2010) 0.77

Spatiotemporal dynamics of the biological interface between cancer and the microenvironment: a fractal anomalous diffusion model with microenvironment plasticity. Theor Biol Med Model (2012) 0.76

Predictive Modeling of Drug Response in Non-Hodgkin's Lymphoma. PLoS One (2015) 0.76

Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat Nanotechnol (2008) 3.78

Intravascular delivery of particulate systems: does geometry really matter? Pharm Res (2008) 3.13

Clinical proteomics: written in blood. Nature (2003) 2.81

Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res (2010) 2.80

Nanomedicine--challenge and perspectives. Angew Chem Int Ed Engl (2009) 2.74

Nanotechnologies for biomolecular detection and medical diagnostics. Curr Opin Chem Biol (2006) 2.74

Seven challenges for nanomedicine. Nat Nanotechnol (2008) 2.59

Geometrical confinement of gadolinium-based contrast agents in nanoporous particles enhances T1 contrast. Nat Nanotechnol (2010) 2.17

Cancer survivorship, a unique and growing cohort in medical practice: radiology perspective. Am J Med (2013) 2.00

An integrated computational/experimental model of tumor invasion. Cancer Res (2006) 1.93

Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. Nat Nanotechnol (2012) 1.85

Design maps for nanoparticles targeting the diseased microvasculature. Biomaterials (2007) 1.72

Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution. J Control Release (2011) 1.72

Tailored porous silicon microparticles: fabrication and properties. Chemphyschem (2010) 1.71

Shaping nano-/micro-particles for enhanced vascular interaction in laminar flows. Nanotechnology (2009) 1.63

The association of silicon microparticles with endothelial cells in drug delivery to the vasculature. Biomaterials (2009) 1.63

What does physics have to do with cancer? Nat Rev Cancer (2011) 1.59

Nanogeometry: beyond drug delivery. Nat Nanotechnol (2008) 1.54

Prediction of drug response in breast cancer using integrative experimental/computational modeling. Cancer Res (2009) 1.53

Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells. PLoS One (2010) 1.49

Predicting drug pharmacokinetics and effect in vascularized tumors using computer simulation. J Math Biol (2008) 1.48

Osmotic pressure beyond concentration restrictions. J Phys Chem B (2007) 1.46

Biotechnology apprenticeship for secondary-level students: teaching advanced cell culture techniques for research. Cell Biol Educ (2002) 1.45

Multistage nanovectors: from concept to novel imaging contrast agents and therapeutics. Acc Chem Res (2011) 1.45

Hesperetin impairs glucose uptake and inhibits proliferation of breast cancer cells. Cell Biochem Funct (2012) 1.44

Predictive oncology: a review of multidisciplinary, multiscale in silico modeling linking phenotype, morphology and growth. Neuroimage (2007) 1.39

T helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions. Proc Natl Acad Sci U S A (2003) 1.37

Antibiological barrier nanovector technology for cancer applications. Expert Opin Drug Deliv (2007) 1.36

Integrated intravital microscopy and mathematical modeling to optimize nanotherapeutics delivery to tumors. AIP Adv (2012) 1.35

Discoidal Porous Silicon Particles: Fabrication and Biodistribution in Breast Cancer Bearing Mice. Adv Funct Mater (2012) 1.35

Mitotic trafficking of silicon microparticles. Nanoscale (2009) 1.35

A physical sciences network characterization of non-tumorigenic and metastatic cells. Sci Rep (2013) 1.33

Cellular association and assembly of a multistage delivery system. Small (2010) 1.32

Biodegradable porous silicon barcode nanowires with defined geometry. Adv Funct Mater (2010) 1.31

Tailoring the degradation kinetics of mesoporous silicon structures through PEGylation. J Biomed Mater Res A (2010) 1.31

Mathematical modeling of cancer progression and response to chemotherapy. Expert Rev Anticancer Ther (2006) 1.30

Multiparameter computational modeling of tumor invasion. Cancer Res (2009) 1.28

Enabling individualized therapy through nanotechnology. Pharmacol Res (2010) 1.28

Nanomedicine in cancer therapy: innovative trends and prospects. Cancer Sci (2011) 1.27

Evolving role of molecular imaging with PET in detecting and characterizing heterogeneity of cancer tissue at the primary and metastatic sites, a plausible explanation for failed attempts to cure malignant disorders. Eur J Nucl Med Mol Imaging (2011) 1.27

Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest (2014) 1.26

The effect of interstitial pressure on tumor growth: coupling with the blood and lymphatic vascular systems. J Theor Biol (2012) 1.25

The preferential targeting of the diseased microvasculature by disk-like particles. Biomaterials (2012) 1.25

Interstitial stress and fluid pressure within a growing tumor. Ann Biomed Eng (2003) 1.25

Multi-stage delivery nano-particle systems for therapeutic applications. Biochim Biophys Acta (2010) 1.23

Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases. Trends Pharmacol Sci (2010) 1.22

Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clin Cancer Res (2013) 1.21

Logic-embedded vectors for intracellular partitioning, endosomal escape, and exocytosis of nanoparticles. Small (2010) 1.19

Identification of thioaptamer ligand against E-selectin: potential application for inflamed vasculature targeting. PLoS One (2010) 1.19

Cooperative, nanoparticle-enabled thermal therapy of breast cancer. Adv Healthc Mater (2011) 1.16

Quantitative mechanics of endothelial phagocytosis of silicon microparticles. Cytometry A (2009) 1.16

Tailoring of the nanotexture of mesoporous silica films and their functionalized derivatives for selectively harvesting low molecular weight protein. ACS Nano (2010) 1.16

Design of bio-mimetic particles with enhanced vascular interaction. J Biomech (2009) 1.15

Intracellular trafficking of silicon particles and logic-embedded vectors. Nanoscale (2010) 1.15

Laparoscopic treatment of splenic artery aneurysms. J Vasc Surg (2009) 1.13

E-selectin-targeted porous silicon particle for nanoparticle delivery to the bone marrow. Adv Mater (2011) 1.12

Nanotechnology for breast cancer therapy. Biomed Microdevices (2009) 1.10

Mesoporous silica chips for selective enrichment and stabilization of low molecular weight proteome. Proteomics (2010) 1.08

Adult and umbilical cord blood-derived platelet-rich plasma for mesenchymal stem cell proliferation, chemotaxis, and cryo-preservation. Biomaterials (2012) 1.07

Human lung cancer cells grown in an ex vivo 3D lung model produce matrix metalloproteinases not produced in 2D culture. PLoS One (2012) 1.07

The transport of nanoparticles in blood vessels: the effect of vessel permeability and blood rheology. Ann Biomed Eng (2008) 1.07

Multistage delivery of chemotherapeutic nanoparticles for breast cancer treatment. Cancer Lett (2012) 1.06

Thioaptamer conjugated liposomes for tumor vasculature targeting. Oncotarget (2011) 1.06

Multistage vectored siRNA targeting ataxia-telangiectasia mutated for breast cancer therapy. Small (2013) 1.05

Near-infrared imaging method for the in vivo assessment of the biodistribution of nanoporous silicon particles. Mol Imaging (2011) 1.04

Nanotechnology and tumor imaging: seizing an opportunity. Mol Imaging (2004) 1.04

Engineering multi-stage nanovectors for controlled degradation and tunable release kinetics. Biomaterials (2013) 1.03

Recommendations of the National Heart, Lung, and Blood Institute Nanotechnology Working Group. Circulation (2003) 1.02

Enhanced MRI relaxivity of Gd(3+) -based contrast agents geometrically confined within porous nanoconstructs. Contrast Media Mol Imaging (2012) 1.02

Tailoring width of microfabricated nanochannels to solute size can be used to control diffusion kinetics. J Control Release (2005) 1.02

An integrated approach for the rational design of nanovectors for biomedical imaging and therapy. Adv Genet (2010) 1.00

Modulating cellular adhesion through nanotopography. Biomaterials (2009) 0.99

A low-voltage electrokinetic nanochannel drug delivery system. Lab Chip (2011) 0.99

Chlamydophila pneumoniae phospholipase D (CpPLD) drives Th17 inflammation in human atherosclerosis. Proc Natl Acad Sci U S A (2012) 0.99

A robust nanofluidic membrane with tunable zero-order release for implantable dose specific drug delivery. Lab Chip (2010) 0.99

Adhesion of microfabricated particles on vascular endothelium: a parametric analysis. Ann Biomed Eng (2004) 0.99

Fractionation of serum components using nanoporous substrates. Bioconjug Chem (2006) 0.98

Mesoporous silica as a membrane for ultra-thin implantable direct glucose fuel cells. Lab Chip (2011) 0.98

Nanoporous surfaces as harvesting agents for mass spectrometric analysis of peptides in human plasma. J Proteome Res (2006) 0.98

Combinatorial selection of DNA thioaptamers targeted to the HA binding domain of human CD44. Biochemistry (2010) 0.96

Comparison of two flow-based imaging methods to measure individual red blood cell area and volume. Cytometry A (2012) 0.95

An integrated multidisciplinary model describing initiation of cancer and the Warburg hypothesis. Theor Biol Med Model (2013) 0.95

The margination propensity of spherical particles for vascular targeting in the microcirculation. J Nanobiotechnology (2008) 0.95

Short and long term, in vitro and in vivo correlations of cellular and tissue responses to mesoporous silicon nanovectors. Small (2012) 0.95

Nanochannel technology for constant delivery of chemotherapeutics: beyond metronomic administration. Pharm Res (2010) 0.94

Delivery of gene silencing agents for breast cancer therapy. Breast Cancer Res (2013) 0.94

Abdominal aortic aneurysm: contrast-enhanced US for missed endoleaks after endoluminal repair. Radiology (2004) 0.94

Vectoring siRNA therapeutics into the clinic. Nat Rev Clin Oncol (2010) 0.94

Modeling of nanotherapeutics delivery based on tumor perfusion. New J Phys (2013) 0.94

Controlled-release microchips. Expert Opin Drug Deliv (2006) 0.94

In silico vascular modeling for personalized nanoparticle delivery. Nanomedicine (Lond) (2012) 0.93

Multistage Mesoporous Silicon-based Nanocarriers: Biocompatibility with Immune Cells and Controlled Degradation in Physiological Fluids. Controll Release Newsl (2008) 0.93

Molecular-targeted nanotherapies in cancer: enabling treatment specificity. Mol Oncol (2011) 0.93

Evaluation of anticancer activity of celastrol liposomes in prostate cancer cells. J Microencapsul (2014) 0.92